Janux Therapeutics, Inc.
JANX
$13.15
-$0.47-3.45%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.73M | 0.00 | 10.00M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.73M | 0.00 | 10.00M | -- | -- |
| Cost of Revenue | 26.81M | 31.55M | 34.63M | 29.18M | 25.06M |
| Gross Profit | -23.08M | -31.55M | -24.63M | -29.18M | -25.06M |
| SG&A Expenses | 11.13M | 10.85M | 10.62M | 10.45M | 9.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.95M | 42.40M | 45.25M | 45.12M | 34.90M |
| Operating Income | -34.21M | -42.40M | -35.25M | -45.12M | -34.90M |
| Income Before Tax | -24.36M | -31.95M | -24.31M | -33.86M | -23.51M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.36M | -31.95M | -24.31M | -33.86M | -23.51M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.36M | -31.95M | -24.31M | -33.86M | -23.51M |
| EBIT | -34.21M | -42.40M | -35.25M | -45.12M | -34.90M |
| EBITDA | -33.74M | -41.93M | -34.75M | -44.58M | -34.38M |
| EPS Basic | -0.39 | -0.51 | -0.39 | -0.55 | -0.38 |
| Normalized Basic EPS | -0.24 | -0.32 | -0.25 | -0.34 | -0.24 |
| EPS Diluted | -0.39 | -0.51 | -0.39 | -0.55 | -0.38 |
| Normalized Diluted EPS | -0.24 | -0.32 | -0.25 | -0.34 | -0.24 |
| Average Basic Shares Outstanding | 62.67M | 62.15M | 62.02M | 61.90M | 61.79M |
| Average Diluted Shares Outstanding | 62.67M | 62.15M | 62.02M | 61.90M | 61.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |